Many viral haemorrhagic fevers caused by viruses, such as Ebola, affect the entire vascular system and have a high mortality rate. This is partly because the virus causes a severe inflammation that destroys blood vessel walls. One to two weeks after the onset of the disease, the body can go into shock and put a patient at risk of dying.
Difficulty controlling the spread of viruses such as Ebola in urban environments is a threat to communities in both Africa and other parts of the industrialised world.
Annexin’s early research project focuses on testing the hypothesis of ANXV multi- level efficacy by simultaneously attacking the spread of the viruses, while improving the patient’s own defences (endothelial, coagulation and immunologic).